On Monday, Shares of AT&T, Inc. (NYSE:T), lost -0.55% to $34.35.
AT&T, is committed to providing its customers reliable communications during the forthcoming hurricane season - before, during and after storms - and has one of the industry’s largest and most advanced business continuity and disaster response programs to keep its networks operational.
Despite predictions, we never know when the next tropical storm or hurricane will hit the coastline. With more than $600 million invested in the Network Disaster Recovery (NDR) program, AT&T’s arsenal of equipment comprises more than 300 technology and equipment trailers that can be quickly deployed, making it one of the nation’s largest and most advanced disaster programs.
The NDR team works closely with other AT&T response teams, local AT&T network personnel, regional Emergency Operations Centers and Local Response Centers to fortify network facilities and equipment, and stage technicians and resources near the storm impact area. In the event of damage, teams are poised to restore and maintain service until permanent repairs can be made. AT&T is the only telecom company to recently become re-certified under new international standards by the Department of Homeland Security for its private-company voluntary disaster preparedness.
AT&T also conducts readiness drills and simulations throughout the year to ensure our networks are prepared and our personnel are ready to respond at a moment’s notice. NDR will complete its 74th full-field recovery exercise this year. Additionally, the AT&T Global Network Operations Center monitors our networks 24/7. Since its inception in 1991, the NDR has responded to more than 70 catastrophes across the U.S.
AT&T Inc. provides telecommunications services in the United States and internationally. The company operates through two segments, Wireless and Wireline. The Wireless segment offers data and voice services, counting local, long-distance, and network access services, in addition to roaming services to youth, family, professionals, small businesses, government, and business customers.
Shares of Humana Inc. (NYSE:HUM), inclined 0.13% to $214.92, during its last trading session.
Humana, declared that it has accomplished its formerly declared sale of the stock of its wholly-owned partner, Concentra Inc. (Concentra), to MJ Acquisition Corporation for about $1.055 billion in cash, subject to customary adjustments. MJ Acquisition Corporation is a joint venture between Select Medical Holdings Corporation (SEM), a leading operator of specialty hospitals and outpatient rehabilitation clinics in the U.S., and Welsh, Carson, Anderson & Stowe XII, L.P., a private equity fund.
The divestiture of Concentra demonstrates the company’s commitment to its formerly declared business portfolio review, ensuring each business supports the company’s integrated care delivery strategy and earns the appropriate return on invested capital.
As formerly revealed, Humana anticipates recognition of a one-time gain from the sale of Concentra during the year ending December 31, 2015 in the range of $1.35 to $1.45 per share, counting the $0.35 per share tax benefit recognized in the quarter ended March 31, 2015 related to the then pending sale.
Humana Inc., together with its auxiliaries, operates as a health and well-being company. The company operates through three segments: Retail, Employer Group, and Healthcare Services.
At the end of Monday’s trade, Shares of Nabors Industries Ltd. (NYSE:NBR), lost -2.03% to $14.45, as crude oil prices dropped on Monday on expectations that Organization of the Petroleum Exporting Countries (Opec) production would remain high, stoking worries of oversupply despite declining US rig operations.
July Brent crude was trading lower by 0.85% to $65 a barrel as of 3:33 p.m. ET recently, while U.S. crude for July delivery was down 0.05% to $60.27 a barrel.
Nabors Industries Ltd., together with its auxiliaries, provides drilling and rig services. The company offers rig instrumentation, optimization software, and directional drilling services. It also provides completion, life-of-well maintenance, and plugging and abandonment of a well.
Finally, Vascular Biogenics Ltd. (NASDAQ:VBLT), ended its last trade with 1.24% gain, and closed at $8.15.
Vascular Biogenics, declared updated interim results from its ongoing Phase 2 study of VB-111 in patients with recurrent glioblastoma (rGBM). Data showed a statistically noteworthy overall survival benefit in patients treated with VB-111 followed by VB-111 in combination with bevacizumab (Avastin(R)) upon disease progression, contrast to patients treated with VB-111 followed by bevacizumab alone (p=0.05). These study results will be presented in greater detail at VBL’s Analyst and Investor Meeting recently, Monday, June 1, 2015, in conjunction with the 2015 American Society for Cancer Oncology (ASCO) Annual Meeting.
These interim Phase 2 results comprise 46 patients with rGBM treated with VB-111; upon disease progression, 23 patients were treated with VB-111 in combination with bevacizumab, and 22 received bevacizumab alone. One patient remains stable on VB-111 alone at 18 months. VB-111 in combination with bevacizumab demonstrated noteworthy improvement in overall survival, with median overall survival of 16 months, contrast to eight months in patients on VB-111 followed by bevacizumab alone (p=0.05). VB-111 also demonstrated a statistically noteworthy improvement over the historical bevacizumab data set from the BELOB trial, which looked at efficacy of bevacizumab, lomustine or a combination of both agents, and stated a median overall survival of eight months for bevacizumab in 50 patients with rGBM (p=0.003).
These data also suggest that VB-111 induces an immuno-therapeutic effect. Of the 46 patients who received VB-111, 25 patients spiked a fever post-dosing of VB-111 at least once, while 21 patients did not. Feverish patients demonstrated a median overall survival of 16 months, contrast to non-feverish patients, who had a median overall survival of 8.5 months (p=0.03). This correlation between clinical efficacy and fever suggests that VB-111 can induce an immune response in patients and supports a role of the immune system as part of VB-111’s mechanism of action. It also strengthens VB-111 preclinical findings, which showed an elevated immune response in tumors of VB-111-treated animals.
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune-inflammatory diseases in Israel. Its lead product candidates comprise VB-111, a gene-based biologic that has accomplished Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; in Phase II clinical trials to treat thyroid cancer; and in Phase I/II clinical trials for the treatment of ovarian cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
